Posts by: Timea Polgar

Timea Polgar

Timea is a Molecular biologist (MSc) & Computational chemist (MSc, PhD), science liaison, and strategic business development and marketing specialist, with 15 years in pharmaceutical R&D, biotech and scientific software development.

September 7, 2016September 7, 2016

Erelzi, Biosimilar to Enbrel, Approve to Treat Certain Psoriasis Patients

News

The U.S. Food and Drug Administration has approved Erelzi (etanercept-szzs), a biosimilar to the already licensed drug Enbrel (etanercept), for the treatment of multiple inflammatory diseases, including psoriasis. Erelzi may be used as ... Read more

June 28, 2016

Role of Interleukin-33 in Skin Psoriasis, Inflammatory Diseases Studied by Researchers

News

Researchers investigated the role of a molecule, interleukin (IL)-33, in a skin psoriasis mouse model to further understand the role of this cytokine in inflammatory diseases. The findings suggest the molecule ... Read more

June 24, 2016

Review of Literature About Psoriasis, Sleep Disturbance Inconclusive

News

Researchers conducted a review of literature focused on psoriasis and sleep disturbances. The findings, although inconclusive largely because of scant data concerning prevalence and the nature of sleep disturbances, led researchers to ... Read more

May 25, 2016May 25, 2016

Psoriasis Biosimilar SB2 by Samsung Bioepis Accepted for FDA Review

News

Samsung Bioepis recently announced in a press release that the U.S. FDA has accepted the company’s Biologics License Application for its biosimilar drug candidate SB2, which references Remicade (infliximab). The drug is indicated ... Read more

May 12, 2016May 12, 2016

anti-TNFα Antibodies Could Decrease Microparticles Present in Severe Psoriasis

News

Psoriasis is associated with atherosclerosis, in which circulating microparticles play a key role. A new research study demonstrated that the increased levels of circulating CD41a and CD31 microparticles were unchanged after anti-IL-12/23 ... Read more

April 27, 2016April 27, 2016

New Psoriasis Treatment Strategies Spurred by Genetic Research

News

A team of researchers from the Vlaams Institute for Biotechnology (VIB) in Belgium discovered a molecular mechanism by which specific mutations in the protein coding gene CARD14 can lead to abnormal inflammation ... Read more

April 18, 2016April 18, 2016

Laser Therapy for Psoriasis Shows No Indication of Koebner Effect, According to Study

News

A recent research study demonstrated that people suffering from plaque psoriasis who received laser treatment did not show evidence of subsequent koebnerization. The research study, “Absence of Koebnerization Following Ablative and ... Read more

April 13, 2016

FDA Approves Eli Lilly’s Psoriasis Drug Taltz

News

The U.S. FDA recently approved a new drug, Taltz (ixekizumab), for the treatment of patients suffering from moderate-to-severe plaque psoriasis. Psoriasis is a long-lasting autoimmune disease characterized by patches of ... Read more